Physician profile
Daniel Geller
NPI 1861706376
$1,432.06
in general payments reported to CMS, 2019-2025
16 companies · $808 in 2025
The $808 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $520 · 2024: $104 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $417.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $117.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.61 | 2021 | |
| Genentech USA, INC. | $111.38 | 2021 | |
| Sanofi-Aventis U.S. LLC | $100.00 | 2021 | |
| Lilly USA, LLC | $91.03 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $82.94 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $74.50 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $67.71 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.99 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $62.43 | 2025 | Entyvio, Gattex |
| Abbvie INC. | $50.21 | 2025 | |
| Celltrion USA INC. | $22.66 | 2025 | Vegzelma |
| Ardelyx, INC. | $20.98 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $15.78 | 2025 | Zenpep |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $15.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.